Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer: Update Bulletin [Feb 2016]

Product Code:
596200576
Publication Date:
February 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK’s National Institute for Health and Clinical Excellence’s (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.

Key Questions Answered in this Update Bulletin:

  • Do the lacklustre results from the interim analysis of the Phase III AFFINITY trial spell the end for custirsen as a mCRPC therapy?
  • While the TOPARP study confirms Lynparza’s activity in BRCA1/2 and ATM gene mutated mCRPC, how likely is it that the agent will be utilised in a wider prostate cancer patient population?
  • How do KOLs view the recommendations published by the UK’s National Institute for Health and Clinical Excellence (NICE) that Xtandi, but not Zytiga, should be used to treat patients with mCRPC in the pre-chemotherapy setting?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved